Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Immunology

• Publication date

  2017-02-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.1601255PMID 28062694PMCID PMC5296279
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions.

  2016cited by this paper
• Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists

  2016cited by this paper
• Immune checkpoint blockade: Releasing the brake towards hematological malignancies.

  2016cited by this paper
• Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies.

  2016cited by this paper
• Improving natural killer cell cancer immunotherapy

  2015cited by this paper
• Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy

  2015cited by this paper
• Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors.

  2015cited by this paper
• Bidirectional interactions of NK cells and dendritic cells in immunotherapy: current and future perspective.

  2015cited by this paper
• Immune checkpoint modulation: rational design of combination strategies.

  2015cited by this paper
• STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity

  2015cited by this paper
• Checkpoint blocking antibodies in cancer immunotherapy

  2014cited by this paper
• Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity.

  2014cited by this paper
• Future approaches in immunotherapy.

  2014cited by this paper
• The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.

  2013cited by this paper
• Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

  2013cited by this paper
• Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.

  2013cited by this paper
• Intratumoral Delivery of Low Doses of Anti-CD40 mAb Combined With Monophosphoryl Lipid A Induces Local and Systemic Antitumor Effects in Immunocompetent and T Cell-Deficient Mice

  2013cited by this paper
• Immune checkpoint blockade immunotherapy to activate anti‐tumour T‐cell immunity

  2013cited by this paper
• Rational combinations of immunotherapeutics that target discrete pathways

  2013cited by this paper
• Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer

  2013cited by this paper
• Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

  2013cited by this paper
• Immune-suppressive properties of the tumor microenvironment

  2013cited by this paper
• CTLA4Ig Inhibits Effector T Cells through Regulatory T Cells and TGF-β

  2013cited by this paper
• Breakthrough of the year 2013. Cancer immunotherapy.

  2013cited by this paper
• Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.

  2013cited by this paper
• Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

  2013cited by this paper
• CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

  2013cited by this paper
• T-cell-independent Antitumor Effects of CD40 Ligation

  2012cited by this paper
• Intratumoral hu14.18–IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention

  2012cited by this paper
• CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

  2011cited by this paper
• Anti‐tumour synergy of cytotoxic chemotherapy and anti‐CD40 plus CpG‐ODN immunotherapy through repolarization of tumour‐associated macrophages

  2011cited by this paper
• Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

  2010cited by this paper
• Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

  2010cited by this paper
• Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules

  2010cited by this paper
• T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.

  2009cited by this paper
• Nanoparticle-Delivered Multimeric Soluble CD40L DNA Combined with Toll-Like Receptor Agonists as a Treatment for Melanoma

  2009cited by this paper
• The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

  2008cited by this paper
• Intratumoral immunocytokine treatment results in enhanced antitumor effects

  2008cited by this paper
• CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors

  2008cited by this paper
• Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG‐oligodeoxynucleotides

  2007cited by this paper
• Synergistic Activation of Macrophages via CD40 and TLR9 Results in T Cell Independent Antitumor Effects1

  2006cited by this paper
• In vivo CD40 ligation can induce T cell‐independent antitumor effects that involve macrophages

  2006cited by this paper
• CD40 Ligation Activates Murine Macrophages via an IFN-γ-Dependent Mechanism Resulting in Tumor Cell Destruction In Vitro 1

  2005cited by this paper
• Breakthrough of the Year

  2004cited by this paper
• Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.

  1998cited by this paper
• Activation of preexisting T cell clones by targeted interleukin 2 therapy.

  1998influential reference
• Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

  1997cited by this paper
• Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.

  1992cited by this paper
• Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines.

  1976cited by this paper
• Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

  year unknowncited by this paper

• Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing

  2025cites this paper
• Aurora Kinase A and B inhibition abrogates ‘Neosis’, a non-mitotic cell division of GBM residual cells and prevents GBM recurrence

  2025cites this paper
• Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy

  2024cites this paper
• A combined radio-immunotherapy regimen eradicates late-stage tumors in mice

  2024influential citation
• Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist

  2023cites this paper
• Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination

  2023cites this paper
• Integrative analysis of multi-omics data for discovery of ferroptosis-related gene signature predicting immune activity in neuroblastoma

  2023cites this paper
• Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma

  2022cites this paper
• Short-course neoadjuvant in situ vaccination for murine melanoma

  2022cites this paper
• Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models

  2021cites this paper
• Utilizing Immunocytokines for Cancer Therapy

  2021cites this paper
• Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model

  2021cites this paper
• Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer

  2021cites this paper
• Distinct Responsiveness of Tumor-Associated Macrophages to Immunotherapy of Tumors with Different Mechanisms of Major Histocompatibility Complex Class I Downregulation

  2021cites this paper
• Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition

  2019cites this paper
• Development of an In Situ Cancer Vaccine via Combinational Radiation and Bacterial‐Membrane‐Coated Nanoparticles

  2019cites this paper
• Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma

  2018influential citation
• Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016

  2017cites this paper
• Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12–13 May 2017

  2017cites this paper